Mode
Text Size
Log in / Sign up

Protein acetylation serves as a critical regulatory hub for inflammation and metabolism in atherosclerosisNew Research Identifies Protein Acetylation as Key Link in Atherosclerosis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that targeting acetylation-regulating enzymes like HDAC inhibitors may offer precision therapy for atherosclerosis.

This systematic review explores the role of protein acetylation (N-terminal and lysine) as a critical link connecting epigenetic regulation, metabolic homeostasis, and inflammatory signaling in atherosclerosis. The authors synthesize evidence indicating that these modifications influence several key pathways, including inflammation, glycolipid metabolism, oxidative stress, energy metabolism, apoptosis, proliferation, and migration.

The review identifies selective HDAC inhibitors and sirtuin activators as promising pharmacological strategies for treating atherosclerosis by targeting acetylation-regulating enzymes. These compounds may offer a pathway toward precision therapies in managing the complex interplay of metabolic and inflammatory signals.

However, the authors note several limitations regarding clinical translation, including contradictory findings and potential off-target effects. While these enzymes show promise, the transition from mechanistic understanding to clinical application remains hindered by these factors. The review suggests that while acetylation is a significant regulatory hub, further research is needed to overcome barriers to clinical use.

How this fits prior evidence

This systematic review extends prior evidence regarding SIRT1 and HDACs as targets for myocardial injury and inflammation. It also builds upon the understanding of metabolic hubs in atherosclerosis, such as the LPC-LPA axis, by identifying protein acetylation as a broader regulatory hub involving glycolipid metabolism and oxidative stress.

Researchers reviewed how protein acetylation acts as a central link between gene regulation, metabolic balance, and inflammatory signals. This process affects several key areas including oxidative stress, energy metabolism, and cell growth. Because it influences so many factors at once, it is considered a critical hub in the development of atherosclerosis.

The review also looked at specific enzymes that regulate this process. Specifically, HDAC inhibitors and sirtuin activators were identified as promising ways to manage these pathways. These methods could potentially lead to more precise treatments for patients with heart disease by targeting the underlying chemical signals.

It is important to note that this research is currently in the early stages of translation. The study noted some challenges, such as contradictory findings and potential off-target effects. Because of these uncertainties, these treatments are not yet ready for standard clinical use. Patients should consult their doctors regarding current treatments.

What this means for you:
Protein acetylation is a key link to heart disease, and certain enzymes may offer future treatment paths.

Common questions

What is the role of protein acetylation in heart disease?

Protein acetylation acts as a critical link between gene regulation, metabolic balance, and inflammatory signals. It influences several factors including oxidative stress, energy metabolism, and cell migration. Because it connects so many different processes, it is considered a central hub in the development of atherosclerosis.

Are there specific treatments being developed for atherosclerosis?

The review identified selective HDAC inhibitors and sirtuin activators as promising ways to treat atherosclerosis. These substances work by targeting the enzymes that regulate protein acetylation, which could lead to more precise therapies in the future.

Is this new treatment available for patients now?

No, these treatments are not yet ready for clinical use. The research highlights several hurdles, including contradictory findings and potential off-target effects. Because of these limitations, you should speak with your doctor about current medical options.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Atherosclerosis (AS) is the leading cause of cardiovascular disease-related mortality worldwide and serves as the core pathological basis for cardiovascular events. Protein acetylation, a widespread and highly dynamic post-translational modification, has emerged as a critical link connecting epigenetic regulation, metabolic homeostasis, and inflammatory signaling, thereby playing an important role in both the initiation and progression of AS. This review systematically summarizes the major forms of protein acetylation, including N-terminal acetylation and lysine acetylation, as well as the key regulatory enzymes involved, such as acetyltransferases (e.g., HATs and NATs) and deacetylases (e.g., HDACs and sirtuins). Particular emphasis is placed on the cell type-specific regulatory roles of acetylation in macrophages, vascular endothelial cells, and vascular smooth muscle cells. Accumulating evidence indicates that protein acetylation modulates gene transcription and protein function through multiple mechanisms, thereby influencing a broad spectrum of AS-related processes, including inflammation, glycolipid metabolism, oxidative stress, energy metabolism, apoptosis, proliferation, and migration. Based on these mechanisms, therapeutic strategies targeting enzymes that regulate acetylation, particularly selective HDAC inhibitors and sirtuin activators, have emerged as promising approaches for the treatment of AS. By integrating recent advances in cellular heterogeneity, plaque stage-specific regulation, and human translational evidence, this review further discusses the therapeutic potential of targeting acetylation-regulating enzymes and critically evaluates the current limitations of this strategy, including contradictory findings, off-target effects, and barriers to clinical translation. Overall, protein acetylation represents a key regulatory hub linking epigenetics, metabolism, and inflammation. A deeper understanding of its regulatory network may provide new insights into the development of precision therapies for AS.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.